Nature Medicine

This journal encompasses original research ranging from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative technologies aimed at improving human health.

More about the journal

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection – the Antibody Mediated Prevention (AMP) trials

A new biomarker appears to be an effective surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains.
Go to the profile of Elena E. Giorgi
Aug 25, 2022